Alistair Rowcroft1, Benjamin P T Loveday2, Benjamin N J Thomson3, Simon Banting4, Brett Knowles5. 1. Department of Surgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 2. Department of Surgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Surgery, University of Auckland, Auckland, New Zealand. 3. Department of Surgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Surgery, University of Melbourne, Melbourne, Australia. 4. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 5. Department of Surgery, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Electronic address: brett.knowles@petermac.org.
Abstract
BACKGROUND: Uveal melanoma (UM) is a rare malignancy with a propensity for metastasis to the liver. Systemic chemotherapy is typically ineffective in these patients with liver metastases and overall survival is poor. There are no evidence-based guidelines for management of UM liver metastases. The aim of this study was to review the evidence for management of UM liver metastases. METHODS: A systematic review of English literature publications was conducted across Ovid Medline, Ovid MEDLINE and Cochrane CENTRAL databases until April 2019. The primary outcome was overall survival, with disease free survival as a secondary outcome. RESULTS: 55 studies were included in the study, with 2446 patients treated overall. The majority of these studies were retrospective, with 17 of 55 including comparative data. Treatment modalities included surgery, isolated hepatic perfusion (IHP), hepatic artery infusion (HAI), transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) and Immunoembolization (IE). Survival varied greatly between treatments and between studies using the same treatments. Both surgery and liver-directed treatments were shown to have benefit in selected patients. CONCLUSION: Predominantly retrospective and uncontrolled studies suggest that surgery and locoregional techniques may prolong survival. Substantial variability in patient selection and study design makes comparison of data and formulation of recommendations challenging.
BACKGROUND: Uveal melanoma (UM) is a rare malignancy with a propensity for metastasis to the liver. Systemic chemotherapy is typically ineffective in these patients with liver metastases and overall survival is poor. There are no evidence-based guidelines for management of UM liver metastases. The aim of this study was to review the evidence for management of UM liver metastases. METHODS: A systematic review of English literature publications was conducted across Ovid Medline, Ovid MEDLINE and Cochrane CENTRAL databases until April 2019. The primary outcome was overall survival, with disease free survival as a secondary outcome. RESULTS: 55 studies were included in the study, with 2446 patients treated overall. The majority of these studies were retrospective, with 17 of 55 including comparative data. Treatment modalities included surgery, isolated hepatic perfusion (IHP), hepatic artery infusion (HAI), transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT) and Immunoembolization (IE). Survival varied greatly between treatments and between studies using the same treatments. Both surgery and liver-directed treatments were shown to have benefit in selected patients. CONCLUSION: Predominantly retrospective and uncontrolled studies suggest that surgery and locoregional techniques may prolong survival. Substantial variability in patient selection and study design makes comparison of data and formulation of recommendations challenging.
Authors: Harry Alexander; Daniel Wen; Michael Chu; Catherine Han; Peter Hadden; Robert Thomas; Adam Bartlett Journal: Br J Radiol Date: 2021-11-10 Impact factor: 3.039
Authors: Vivian Chua; Jane Mattei; Anna Han; Lauren Johnston; Kyleigh LiPira; Sara M Selig; Richard D Carvajal; Andrew E Aplin; Sapna P Patel Journal: Clin Cancer Res Date: 2020-10-15 Impact factor: 12.531
Authors: Sachin Modi; Tom Gibson; Ganesh Vigneswaran; Shian Patel; Matthew Wheater; Ioannis Karydis; Sanjay Gupta; Arjun Takhar; Neil Pearce; Christian Ottensmeier; Brian Stedman Journal: Melanoma Res Date: 2022-04-01 Impact factor: 3.199
Authors: T M L Tong; M K van der Kooij; F M Speetjens; A R van Erkel; R W van der Meer; J Lutjeboer; E L van Persijn van Meerten; C H Martini; R W M Zoethout; F G J Tijl; C U Blank; M C Burgmans; E Kapiteijn Journal: Trials Date: 2022-02-13 Impact factor: 2.279
Authors: Thomas Helmberger; Rita Golfieri; Maciej Pech; Thomas Pfammatter; Dirk Arnold; Roberto Cianni; Geert Maleux; Graham Munneke; Olivier Pellerin; Bora Peynircioglu; Bruno Sangro; Niklaus Schaefer; Niels de Jong; José Ignacio Bilbao Journal: Cardiovasc Intervent Radiol Date: 2020-09-21 Impact factor: 2.740